A prespecified secondary aim was to similarly examine the extent to which the MGI+HOXB13:IL17BR predicts the risk of breast cancer-specific mortality among tamoxifen-untreated ER-positive, node-negative patients. Here, ESR1 is linked to breast carcinoma.